Medicamen Organics Ltd (MEDIORG) — shareholding pattern, promoter holding, financials and share price
About Medicamen Organics Ltd (MEDIORG)
Medicamen Organics Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as MEDIORG and on the BSE under scrip code 92885. Its ISIN is INE0PE401018.
Incorporated in 1995, Medicamen Organics Ltd develops, manufactures, and distributes a broad range of pharmaceutical dosages including generic dosage [1]
Medicamen Organics Limited specializes in developing, manufacturing, and distributing a diverse range of pharmaceutical products including tablets, capsules, syrups, and dry powders.
The company is strategically focused on global expansion, notably entering the Nepalese market through a partnership with Medi Hub Organic Limited, complemented by a new subsidiary, Grande Etoile Pharmaceuticals.
Listed peers in Pharmaceuticals: Welcure Drugs & Pharmaceuticals Ltd, Sunrest Lifescience Ltd, Chandra Bhagat Pharma Ltd, Medistep Healthcare Ltd, Gujarat Terce Laboratories Ltd, Venmax Drugs & Pharmaceuticals Ltd.
Valuation & Returns
10 Jul 2026At ₹22.25 a share on 10 Jul 2026, Medicamen Organics Ltd (MEDIORG) was valued at a price-to-earnings ratio of -6.73x against an industry P/E of 36.41x and a price-to-book of 0.94x on a book value of ₹23.61 per share. Solomo computes return on equity of -13.99% and return on capital employed of -10.62% from filed results.
- P/E
- -6.73x
- Industry P/E
- 36.41x
- P/B
- 0.94x
- EPS (TTM)
- ₹3.66
- Book value / share
- ₹23.61
- ROE
- -13.99%
- ROCE
- -10.62%
- ROA
- -7.79%
- Debt / equity
- 0.5x
- Dividend yield
- 0%
- EBITDA margin
- -16.22%
- 52-week range
- ₹19.1 – ₹45
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Medicamen Organics Ltd (MEDIORG) reported revenue of ₹22.63 crore, net profit of ₹-4.02 crore and earnings per share of ₹-3.3. That compares with revenue of ₹38.19 crore and net profit of ₹4.05 crore in Mar 2025. Figures are consolidated, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹4.78 crore and net profit ₹-6.06 crore (consolidated).
| Metric | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|
| Revenue (₹ cr) | 25.27 | 38.19 | 22.63 |
| Net profit (₹ cr) | 2.62 | 4.05 | -4.02 |
| EPS (₹) | 3.05 | 3.46 | -3.3 |
| Measure | 5Y | 3Y | 1Y |
|---|---|---|---|
| Sales growth | 3.33% | 20.92% | 51.13% |
| Profit growth | 99.94% | 228.46% | 54.58% |
| Stock price CAGR | - | - | -42% |
Ownership Summary
Mar 2026As of Mar 2026, promoters hold 59.73% of Medicamen Organics Ltd (MEDIORG). Market capitalisation was ₹27 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Sep 2024.
Largest disclosed public shareholders in Mar 2026: SB OPPORTUNITIES FUND I 1.64%, ABHISHEK KAUSHIK 1.21%, AKILANDESWARI SELVAMURTHY 1.18%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Mar 2026 | 59.73% | - | - | - | - |
| Sep 2025 | 59.73% | - | - | - | - |
| Mar 2025 | 59.73% | - | - | - | - |
| Sep 2024 | 59.69% | - | - | - | - |